The need for access to anti-TB drugs in India: An interview with Anand GroverSarah Thanawala·April 1, 2023
World TB Day coincides with the Indian Patent Office rejecting J&J’s application to extend its patent on anti-tuberculosis drug BedaquilineSarah Thanawala·March 24, 2023
Panel discussion on Intellectual Property and the Constitution: accessibility, vaccine waivers and content creationTaera Singh·April 16, 2022
Leaked Text Incorporates Stringent TRIPS Plus Elements, Global Calls for Rejection IncreaseRicha Chintan·April 12, 2022
IP vs. the right to repair: deciphering the legal conundrumPriya Raghuvanshi and Aryaveer Hooda·October 11, 2021
COVID-19 and the Shortage of Drugs: A Case for Compulsory LicensingSri Hari Mangalam and Pritish Raj·May 29, 2021
Covid19: Why aren’t you buying all doses; when will you disburse 50% of doses to states; what is the rationale for differential pricing: SC to CentreThe Leaflet·April 30, 2021
Plea filed in SC seeking directions to Centre to issue compulsory licenses for patents on Remdesivir, Favipiravir, TocilizumabThe Leaflet·April 29, 2021
Bombay HC directs Centre to decide representation seeking ‘compulsory licenses’ to two patented anti-TB drugsThe Leaflet·March 10, 2021
Patent and Patient Rights in COVID-19: Is the Right to Exclusivity a Hamlet Question?Justice Prabha Sridevan·October 8, 2020
